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Introduction
Chronic liver damage caused by a variety of insults (e.g. infections such as hepatitis C; alcohol; obesity; genetic diseases 25 such as Willson's disease; autoimmune diseases such as primary biliary cirrhosis) results in hepatic fibrosis that limits the ability of the liver to regenerate, leading to cirrhosis, hepatocellular carcinoma and end-stage liver failure. 1 There are currently no treatments for hepatic fibrosis, therefore fibrosis progression is 30 responsible for a significant proportion of the morbidity and mortality associated with liver disease. 2 Depending on the hepatic insult, the localisation and distribution of hepatic fibrosis may vary within the liver lobule. For example, alcoholic hepatitis produces centrilobular necrosis and fibrosis whereas viral 35 hepatitis and cholestatic liver disease cause hepatic damage and fibrosis emerging from the portal tract (periportal region of the lobule). 1 Accordingly, in the development of effective antifibrogenic drugs for the liver, there is a need to test for therapeutuic efficacy using at least two experimental models of 40 liver fibrosis -including at least a centrilobular as well as periportal model of fibrosis. 1, 3 The most commonly used model for periportal fibrosis is bile duct ligation (BDL), a surgical procedure involving the double 45 ligation of the common bile duct. 4 The pathology resulting from BDL is similar to that seen in human chronic cholestatic disease:-initiation of a ductular reaction and activation of portal tract fibroblasts leading to portal-portal bridging fibrosis. [4] [5] [6] However, BDL involves a surgical procedure that requires expertise. 50 Surgery and the severity of the procedure often result in a significant level of mortality. 4 This high level of mortality limits the long term use of BDL in animals (generally no longer than 4 weeks ). 7 Additionally, although the procedure can be reversed by additional surgery, this is unlikely to occur due to cost, time and 55 welfare constraints. The procedure in the United Kingdom is therefore classified as "severe" under the Animals (Scientific Procedures) Act 1986.
Methapyrilene (MP) [N,N-dimethyl-N'-Pyridyl-N' thienylmethyl)-1,2-ethanediamine] is an H1 receptor antagonist that was used as a sedative and anti-histamine until its withdrawal in the late 1970s, when it was demonstrated to promote hepatocellular carcinoma in chronically-dosed rats. 8 Subsequent work demonstrated that MP is a periportal hepatotoxin in rats. [9] [10] [11] [12] [13] [14] [15] [16] [17] Based on the observation that MP causes periportal hepatic damage, we hypothesised that the chronic dosing of MP to rats would lead to a less severe, more controllable and reversible periportal fibrosis. We therefore compared the fibrosis generated 5 by BDL and MP in rats. The data in this paper demonstrate for the first time that MP produces a qualitatively similar fibrosis to BDL. MP fibrosis therefore represents a more refined and superior model of hepatic periportal fibrosis than the BDL model.
10
Results MP treatment caused a cholestatic injury and an increase in liver weight. 15 To determine the effects of chronic MP dosing in rats, MP was administered by oral gavage at a dose of 150mg MP/kg body weight 3 times per week. This dose was chosen because it has previously been shown to cause moderate hepatic damage after 20 acute administration.
20 Table 1 shows that this dose of MP did not cause a loss of body weight, but similarly to BDL, caused a significant decrease in gain of weight compared to their respective controls. Figure 1a indicates that MP treatment significantly increased serum ALP levels with non-significant 25 increases in ALT and AST serum enzyme levels. In contrast, BDL significantly increased serum ALP, ALT and AST levels compared to sham treated rats. Serum γ-glutamyl transpeptidase (gGT) was undetectable in control animals (vehicle and sham controls) but was detectable in 3 of 5 MP treated rats and all rats 30 subject to 14 days BDL (data not shown). Measurement of liver weight indicated that MP administration and BDL were also associated with a significant increase in liver weight as a proportion of total body weight ( Figure 1b ). There was no mortality associated with the administration of MP, whereas BDL 35 caused 30% mortality after 14 days.
MP treatment caused portal tract inflammation and initiated an hepatic regenerative response. 40 To determine whether liver injury caused by MP administration resulted in qualitatively similar pathological lesions, MP was administered to rats for 3 or 6 weeks, with an additional group allowed to recover after 3 weeks MP treatment to determine whether pathological changes were reversible. 45 Liver sections from MP treated and control animals were stained with H&E and compared to liver sections from rats culled 14 days after BDL surgery. Control animals showed occasional infiltrating leucocytes in the periportal region whereas both MP 50 and BDL treated rats showed cell injury and necrosis in the periportal regions accompanied with marked significant increases in periportal inflammatory cells (Figure 2) . MP treatment for 6 weeks did not significantly increase inflammatory cell recruitment over that present at 3 weeks. However, staining 55 sections for neutrophils indicates that there was a progressive increased recruitment of neutrophils to the periportal regions of the liver lobule (Supplementary Figure 1) . These adverse effects to MP were specific to the liver as judged macroscopically (data not shown). Limited pathological examination of non-hepatic MP treatment caused an expansion of pro-fibrogenic cells and periportal fibrosis.
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Myofibroblasts and fibroblasts are recognised to play a fundamental role in deposition of extracellular matrix during hepatic fibrogenesis. [22] [23] [24] Of these populations, portal tract fibroblasts have been implicated as the primary fibrogenic cell population involved in deposition of fibrotic extracellular matrix 80 during the initial stages of periportal fibrosis. Myofibroblasts are a pro-fibrogenic cell population associated with peri-sinusoidal and centrilobular injury, 22, 23, 27 and express 95 the marker α-SMA. 28 Figure 5 demonstrates that only smooth muscle cells surrounding portal arterioles expressed α-SMA in liver sections from control rats. In BDL and MP treated rats, there was a significant increase in the number of periportal α-SMA positive cells. Liver sections from rats treated with MP for 6 100 weeks had significantly more periportal α-SMA positive cells than rats treated for 3 weeks. Similar to periportal vimentin staining, the significant increase in the number of periportal α-SMA positive cells seen in rats after 3 weeks MP was reversible after 3 weeks vehicle treatment.
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Sirius red staining for collagen fibres showed that both BDL and MP treatment induced significant periportal fibrosis ( Figure 6 ). Since biliary fibrosis severity can be somewhat heterogeneous throughout the liver, image analysis was performed (by an 110 experimenter blinded to the identity of the treatments as outlined in the methods section) on 10 randomly selected portal tracts per section per rat to robustly test the effects of MP on fibrogenesis and recovery. Sirius red staining quantification ( Figure 6 ) and hepatic hydroxyproline contents (Supplementary Figure 4) 115 confirm MP treatment for both 3 and 6 weeks caused a significant increase in hepatic collagen content and therefore fibrosis. Prolonged treatment with MP (6 weeks) led to a significant increase in periportal fibrosis compared to that seen after 3 weeks and 14 days BDL (Figure 6 ). The increase in periportal fibrosis after 3 weeks was reversible as rats treated with 3 weeks MP 5 followed by 3 weeks vehicle no longer showed significant periportal collagen deposition. Central veins appeared similar between MP treated and control animals indicating that MP primarily caused periportal damage and fibrosis.
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MP treatment caused a ductular reaction.
Ductular reaction is a regenerative response involving the significant expansion of CK-19 positive cholangiocytes and it is thought to play an important role in fibrogenesis. 29 Figure 7 15 shows that both BDL and MP gave rise to a ductular reaction with clear evidence of bile duct expansion. The reaction was significantly more severe after 6 weeks than 3 weeks of MP treatment, with a reverse in ductular reaction within 3 weeks after MP withdrawal ( Figure 7 ).
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Chronic MP treatment caused a significant and reversible upregulation of expression of genes associated with fibrogenesis.
The expression of genes associated with fibrogenesis was 25 measured to place the changes observed in the liver after MP treatment in a more quantitative context to BDL. Table 2 demonstrates that both BDL and MP treatment up-regulated the expression of a variety of mRNAs associated with fibrogenesis -α-SMA, collagen 1A1 (COL1A1), MMP-2, TGF-β1, TGF-β2, 30 TIMP-1 and vimentin. The expression of these genes also returned to basal levels in the group of rats treated with MP for 3 weeks followed by a 3 week recovery.
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Discussion
A major complicating factor in chronic liver disease is fibrosis, for which there are no treatments indicated except transplantation. Fibrosis therefore remains a major determining 40 factor in the high rate of mortality arising from chronic liver disease worldwide. 1,2 Models of periportal fibrosis are important in research into anti-fibrogenics. This is because it is recommended that anti-fibrogenics are tested in both at least one centrilobular and periportal model of fibrosis (due to the different 45 cell types contributing to fibrogenesis 1, 3, 25 ). In view of the limitations associated with the BDL model, chronic MP dosing was investigated as an alternative.
Chronic MP administration of rats significantly elevated serum 50 ALP levels suggesting that MP caused a cholestatic injury with evidence of a trend toward hepatocyte necrosis ( Figure 1 ). BDL conversely significantly elevated all liver serum markers. The absence of significant ALT and AST serum activity after MP treatment is likely because the dose chosen caused less severe 55 injury compared to BDL and hepatic regenerative pathways were sufficient to remove and replace damaged hepatocytes between MP doses. Importantly, MP treatment unlike BDL caused no mortality and there were no complications associated with the procedure.
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Qualitative similarities between the pathology of BDL-and MPinduced fibrosis were seen at several levels. Inflammation is generally a pre-requisite for the development of fibrosis. Based on sirius red stained liver sections, the severity of fibrosis in BDL sits between the severities seen between 3 and 6 weeks of MP treatment.
Spontaneous reversal of fibrosis is recognised to occur in some 90 patients where the underlying cause of hepatic insult is successfully treated, however the processes that underlie this reversal are poorly understood. 1 The severity of periportal fibrosis in MP treated rats correlated with the number of profibrogenic cells. The resolution of fibrosis seen in rats treated 95 with MP for 3 weeks followed by vehicle for 3 weeks is therefore likely to be the result of apoptosis or reversal of the profibrogenic phenotype of these populations. This may result from a decline in inflammation and associated pro-fibrogenic growth factors released from inflammatory cells. Expression of hepatic 100 TGF-β1 and TIMP-1 mRNAs to control levels in rats treated with MP for 3 weeks followed by vehicle for 3 weeks (Table 2) , supports this hypothesis. The ease of reversal in this model facilitates its use as a method to study the reversal of periportal fibrosis, along with other rodent models of xenobiotic induced 105 biliary fibrosis, 31,32 as an alternative to BDL reversal.
Ductular reaction promotes fibrosis development as ductules are pro-fibrogenic through the release of a range of chemokines, cytokines and growth factors that promote inflammation and 110 fibrosis. 29, 33 The expansion of ductal cells was quantified by CK-19 staining and showed that MP caused a ductular reaction similarly to BDL in rats (Figure 7) . The ductular reaction induced by MP was also shown to be reversible. Chronic MP treatment caused liver damage and activation of a ductular reaction in a 115 more gradual manner relative to BDL. The use of a MP model for the study of this phenomenon would therefore allow for a longer time frame for study of the early stages of a ductular reaction.
It is clear from much of the data in this paper that BDL resulted in higher levels of many biomarkers of liver disease when 5 compared to MP treatment at the dose employed. This is because BDL causes severe, constant and uncontrollable hepatic damage which likely is the cause for the high rate of mortality associated with the procedure. Dosing of MP is a more controllable model which also allows for some degree of hepatic regeneration to 10 occur. There is also the option of modifying the doses employed to increase the severity of injury. The MP model may therefore be a superior model of human hepatic periportal fibrosis. This is primarily because in humans with chronic hepatic disease, fibrosis develops gradually and is frequently reversible when the 15 underlying cause is removed. In terms of potential drug interactions, the dosing of MP has been shown to cause a reduction in CYP2C11 and CYP3A activity in rats in vivo although the activity of the CYP1A and CYP2B 20 families are unaffected by MP treatment.
19 Knockout of the H1 receptor has been shown to have no effect on hepatic injury in a murine model of liver injury 34 -the antagonistic action of MP on the H1 receptor is therefore not predicted to have a significant effect on MP induced hepatic damage. If the efficacy of anti-25 fibrogenics is being tested in periportal fibrosis generated by MP, drug interactions should be considered in analysis of results. MP is an H1 antagonist in the rat 35 and mast cells increase in number in fibrotic tissue 36 and contribute to the progression of fibrosis via the release of mediators such as histamine, tryptase, heparin and 30 fibroblast growth factors. 37 Furthermore, the proliferation of small cholangiocytes has been shown to be promoted by histamines. 38 Most compounds used in fibrosis studies will have "off target" effects with respect to toxicity that may also modulate subsequent fibrogenic responses. With drugs, there 35 may be effects associated with known pharmacological targets (e.g. paracetamol and cyclooxygenase inhibition 39 ). However, even the commonly employed centrilobular hepatotoxin CCl 4 (which injures hepatocytes via a CYP2E1-mediated lipid peroxidation mechanism 1 ) has been shown to inhibit protein 40 kinase C activity by 50% in cells at a concentration of 1uM. 40 It has been shown here for the first time that chronic administration of MP leads to development of reversible hepatic periportal fibrosis with characteristics qualitatively similar to that 45 seen after BDL in male rats, but without the requirement for surgery, distress and high mortality rates. Use of MP as an alternative to BDL would allow for modulation of fibrosis severity through changing the dosing regimen, whilst allowing fibrosis formation to be reversed if required. Chronic MP 50 administration is therefore a refined alternative to BDL producing a reproducible model of reversible periportal fibrosis in rats. For all immunostaining, sodium citrate antigen retrieval was used to expose epitopes and 100 primary antibodies were used at a 1:250 dilution. Di-amino benzidine (Dako, Ely, UK) was used to visualise secondary antibody binding to primary antibodies (anti-mouse/HRP or anti rabbit/HRP, 1:250 dilution, Dako). All sections were counterstained with haematoxylin prior to mounting. 105 Inflammatory cell or neutrophil infiltration were calculated by counting the number of periportal leucocytes in and around 6 random portal tracts per section from the H&E or esterase stained sections respectively. PCNA immunostaining was quantified by 110 counting the number of PCNA positive hepatocytes and cholangiocytes around 5 random portal tracts per section at x20 magnification. Sirius red, α-SMA, CK-19 and vimentin staining were quantified by densitometry analysis using Qwin software (Leica, Wetzlar, Germany) after manually specifying the 115 threshold for positive staining. The threshold was selected to ensure consistent measurement of staining across different sections. Analysis was carried out at x10 magnification, focusing on portal tracts in 10 random fields per section. All quantifications were carried out by a researcher blinded to the treatment groups. For whole liver lobule sirius red quantification, 5 slides were scanned using a Leica SCN400 slide scanner and then analysed for positive staining using the accompanying slidepath software.
Materials and methods
55
Animal studies
Quantitative real-time PCR
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RNA was purified from liver samples using TRIzol (Life Technologies, Paisley, UK), DNAse-treated using RQ1 DNAse (Promega, Southampton, UK) and complementary DNA then synthesised using MML-V reverse transcriptase (Promega), following the manufacturer's instructions. Quantitative real-time 
Hydroxyproline assay
Hydroxyproline assays were carried out using the Quickzyme hydroxyproline assay kit (2B Scientific, Upper Heyford, UK). Samples were prepared by incubating liver samples in 6M HCl (10mg wet weight/100ul HCl) overnight at 110°C. Following 40 acid hydrolysis, the samples were centrifuged at 13,000rpm for 15 minutes in a desktop centrifuge and the supernatant retained for the assay. 
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